Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06318897
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-03-13
Brief Title:
Open-label Single Center Single-arm Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-29
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-13
First Submit QC Date:
March 13 2024
Study First Post Date:
2024-03-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-30
Last Update Post Date:
2024-05-31
Last Update Post Date Type:
ACTUAL